Cell Adhesion & Migration-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2022-11-21 lovebanana

偏重的研究方向：机制;靶点;肿瘤转移
经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。

42 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2021-09-28 ms8000000799725838

细胞粘附复合物的组装
ECM分子的生物学功能和分子相互作用
细胞骨架可塑性和相关信号级联
细胞融合和细胞嵌入
免疫突触形成
轴突生长和引导
细胞生物力学
生物材料
成像技术的发展

58 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2021-12-27 MS68862005

RUNNINGTITLE和TITLE的区别？

57 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2021-12-27 msSSSSSD

RUNINGTITLE的撰写方法？

43 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2020-04-28 ms6596549308483070

审稿速度:4.0
经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。

101 0

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2019-11-13 LX6990064

审稿速度:6.0 | 投稿命中率:50.0
经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。

139 0

[GetPortalCommentsPageByObjectIdResponse(id=2101703, encodeId=3e7d2101e0303, content=偏重的研究方向：机制;靶点;肿瘤转移 经验分享：请问，审稿很慢吗？一个月要不要催？着急毕业。审稿一个月了呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Mon Nov 21 08:10:14 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055571, encodeId=7f3210555e15b, content=细胞粘附复合物的组装 ECM分子的生物学功能和分子相互作用 细胞骨架可塑性和相关信号级联 细胞融合和细胞嵌入 免疫突触形成 轴突生长和引导 细胞生物力学 生物材料 成像技术的发展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdca5589562, createdName=ms8000000799725838, createdTime=Tue Sep 28 08:30:46 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104781, encodeId=265b1104e815d, content=RUNNINGTITLE和TITLE的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104782, encodeId=857d1104e820c, content=RUNINGTITLE的撰写方法？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859941, encodeId=ea82859941e2, content=审稿速度:4.0 经验分享：一篇综述，2019年10月投稿，2020年2月收到审稿意见（minor revise），3月返回，3日后接收。总体来说投稿比较顺利。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77f15414044, createdName=ms6596549308483070, createdTime=Tue Apr 28 08:25:40 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579807, encodeId=758f5e98072e, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：我是今年6月22号投的稿，7月1号送外审，8月29号小修，9月10号返回，次日with editor，到9月24号变为under review，暂时没有然后了，返修两个月了，没有动静，急也没用。年发文量很少，大概50篇，从发表的文章来看，还是要有点数据量的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=154986814, createdName=LX6990064, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563561, encodeId=44cf56356184, content=有没有投这个杂志，接收的呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad801733342, createdName=1def2087m05(暂无匿称), createdTime=Fri Nov 23 17:25:00 CST 2018, time=2018-11-23, status=1, ipAttribution=)]

2018-11-23 1def2087m05(暂无匿称)

有没有投这个杂志，接收的呀？

136 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务